Zhong Guo Jing Ji Wang·2025-05-08 05:33Core Viewpoint - Shenzhen Qianhai Shengtai Investment Enterprise plans to reduce its stake in Chengda Pharmaceutical by up to 4,894,943 shares, representing 3.23% of the company's total share capital, due to the shareholder's operational needs [1][2] Group 1: Shareholder Information - Shenzhen Qianhai Shengtai holds 15,901,840 shares, accounting for 10.50% of the company's total share capital after excluding repurchased shares [1][2] - The planned reduction will occur within three months from May 30, 2025, to August 29, 2025, through block trading [1] - The shareholder is not a controlling shareholder or actual controller of the company, and the reduction will not lead to a change in control or significantly impact the company's governance structure [2] Group 2: Company Financials - Chengda Pharmaceutical's initial public offering raised a total of 1.757 billion yuan, with a net amount of 1.621 billion yuan after deducting issuance costs [3] - The company reported a revenue of 333.13 million yuan in 2024, a decrease of 19.59% compared to 2023 [4][5] - The net profit attributable to shareholders was -28.10 million yuan in 2024, a decline of 130.89% year-on-year [4][5] - For Q1 2025, the company achieved a revenue of 76.31 million yuan, down 24.37% year-on-year, with a net loss of -1.40 million yuan [6]